A randomized controlled trial of flunarizine as add‐on therapy and effect on cognitive outcome in children with infantile spasms

Purpose:  Cognitive impairment is observed commonly in children with a history of infantile spasms (IS). The goal of this study was to prospectively examine the effect on cognitive outcome of a neuroprotective agent used as adjunctive therapy during treatment of the spasms.

[1]  J. Osborne,et al.  The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: Evidence from the United Kingdom Infantile Spasms Study , 2011, Epilepsia.

[2]  I. Bezprozvanny,et al.  Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[3]  Joseph Classen,et al.  L-Type Voltage-Gated Ca2+ Channels: A Single Molecular Switch for Long-Term Potentiation/Long-Term Depression-Like Plasticity and Activity-Dependent Metaplasticity in Humans , 2010, The Journal of Neuroscience.

[4]  Anthony L. Johnson,et al.  Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial , 2010, Archives of Disease in Childhood.

[5]  Arthur Partikian,et al.  Neurodevelopmental and Epilepsy Outcomes in a North American Cohort of Patients With Infantile Spasms , 2010, Journal of child neurology.

[6]  D. Prasad,et al.  Isradipine antagonizes hypobaric hypoxia induced CA1 damage and memory impairment: Complementary roles of L-type calcium channel and NMDA receptors , 2009, Neurobiology of Disease.

[7]  R. Riikonen,et al.  Favourable prognostic factors with infantile spasms. , 2008, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[8]  B. Neville,et al.  The treatment and management of alternating hemiplegia of childhood , 2007, Developmental medicine and child neurology.

[9]  A. Lux.  Is hypsarrhythmia a form of non‐convulsive status epilepticus in infants? , 2007, Acta neurologica Scandinavica. Supplementum.

[10]  G. Solomon,et al.  Topiramate for the Treatment of Infantile Spasms , 2006, Journal of child neurology.

[11]  J. Osborne,et al.  The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial , 2005, The Lancet Neurology.

[12]  Anthony L. Johnson,et al.  The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial , 2004, The Lancet.

[13]  G. Holmes,et al.  Effects of nimodipine on the behavioral sequalae of experimental status epilepticus in prepubescent rats , 2004, Epilepsy & Behavior.

[14]  S. Shinnar,et al.  Long‐term Cognitive Outcomes of a Cohort of Children with Cryptogenic Infantile Spasms Treated with High‐dose Adrenocorticotropic Hormone , 2004, Epilepsia.

[15]  R. Regenthal,et al.  Anticonvulsant profile of flunarizine and relation to Na(+) channel blocking effects. , 2004, Basic & clinical pharmacology & toxicology.

[16]  L. Carmant,et al.  Launching a Research Initiative: The Canadian Pediatric Epilepsy Network (CPEN) , 2002, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[17]  L. Carmant.  Infantile spasms: West syndrome. , 2002, Archives of neurology.

[18]  Y. Toribe.  High-dose vitamin B6 treatment in West syndrome , 2001, Brain and Development.

[19]  E. Gaily,et al.  Infantile spasms: diagnosis and assessment of treatment response by video‐EEG , 2001, Developmental medicine and child neurology.

[20]  E. Gaily,et al.  Treatment of Infantile Spasms: Results of a Population‐Based Study with Vigabatrin as the First Drug for Spasms , 1999, Epilepsia.

[21]  N. Bayley.  Bayley Scales of Infant Development , 1999 .

[22]  M. Cilio,et al.  Vigabatrin Versus ACTH as First‐Line Treatment for Infantile Spasms: A Randomized, Prospective Study , 1997, Epilepsia.

[23]  D. Choi,et al.  The calcium channel blocker nifedipine attenuates slow excitatory amino acid neurotoxicity. , 1990, Science.

[24]  D. Choi,et al.  Glutamate neurotoxicity and diseases of the nervous system , 1988, Neuron.

[25]  E. Wyllie.  The Treatment of Epilepsy: Principles and Practice , 1997 .

[26]  J. Leysen,et al.  Ca++ and Na+ channels involved in neuronal cell death. Protection by flunarizine. , 1991, Life sciences.